艾地苯醌对老年稳定性冠心病患者认知功能障碍的改善作用Idebenone improves cognitive dysfunction in elderly patients with stable coronary heart disease
陈啸;丁兆生;李佟;张嘉玮;
摘要(Abstract):
目的探讨艾地苯醌对老年稳定性冠心病患者认知功能障碍的改善作用。方法选取2018年及2019年,两年间在江苏省荣军医院住院及门诊就诊的,合并有认知功能障碍的老年稳定性冠心病患者64例,采用随机数法将患者分为药物组和对照组,各32例。两组患者均按各自需要完善常规治疗,药物组在其基础上给予艾地苯醌治疗。采用蒙特利尔认知评估量表(MoCA)、汉密顿焦虑量表(HAMA)和汉密顿抑郁量表(HAMD)分别评估认知功能、焦虑情绪和抑郁情绪,并比较两组患者评估结果的差异。结果 (1)两组患者在基线状态下,MoCA评分、HAMA评分、HAMD评分差异均无统计学意义(P分别为0.647、0.306、0.242)。(2)药物组患者治疗后,与基线状态相比,MoCA各项评分有所增加,尤其在延迟回忆[(3.94±0.25)vs(3.06±0.72)]和总分值[(23.56±1.37)vs(22.06±1.99)]方面差异有统计学意义(P=0.000和P=0.001),HAMA评分[(17.53±2.40)vs(15.97±2.22)]和HAMD评分[(20.03±2.35)vs(17.44±1.90)]均有所降低,差异有统计学意义(P=0.009和P=0.000)。(3)药物组患者治疗后,与对照组相比,MoCA各项评分均增加,尤其在延迟回忆[(3.94±0.25)vs(3.13±0.61)]和总分值[(23.56±1.37)vs(22.41±1.58)]方面差异有统计学意义(P=0.000和P=0.003),HAMA评分[(17.53±2.40)vs(18.63±2.59)]和HAMD评分[(20.03±2.35)vs(20.63±1.90)]均有所降低,差异有统计学意义(P=0.000和P=0.000)。(4)治疗前后,两组患者间心肺功能比较,差异均无统计学意义(P=0.763和P=0.146)。结论艾地苯醌能够对老年稳定性冠心病患者的认知功能障碍起到一定改善作用。
关键词(KeyWords): 艾地苯醌;冠心病;认知功能障碍
基金项目(Foundation): 无锡市卫生健康科技成果和适宜技术推广项目(T201932)
作者(Authors): 陈啸;丁兆生;李佟;张嘉玮;
DOI: 10.13799/j.cnki.mdjyxyxb.2020.03.023
参考文献(References):
- [1] 杨郑,孙颖.老年心血管病与认知功能障碍的相关性[J].中华老年心脑血管病杂志,2017,19(1):97-99.
- [2] 中华医学会老年医学分会老年神经病学组,老年人认知障碍诊治专家共识撰写组.中国老年人认知障碍诊治流程专家建议[J].中华老年医学杂志,2014,33(8):817-825.
- [3] ROBERTS R O,KNOPMAN D S,GEDA Y E,et al.Coronary heart disease is associated with non-amnestic mild cognitive impairment[J].Neurobiol Aging,2010,3l(11):1894-1902.
- [4] BLECKWENM M,KLEINEIDAM L,WAGNER M,et al.Impact of coronary heart disease on cognitive decline in Alzheimer’s disease:a prospective longitudinal cohort study in primary care[J].Br J Gen Pract.2017,67(5):111-117.
- [5] 胡晓丹,蒙云.艾地苯酿治疗急性脑梗死后认知功能障碍疗效研究[J].现代医药卫,2019,35(3):415-417.
- [6] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
- [7] 王炜,靳慧,丁斌蓉,等.北京版MoCA在长沙地区缺血性脑血管病人群中的应用及长沙版MoCA的形成[J].中国神经精神疾病杂志,2011,37(6):349-353.
- [8] 张明园,何燕玲.精神科评定量表手册[M].第二版.长沙:湖南科学技术出版社,2015:181-183.
- [9] 张明园,何燕玲.精神科评定量表手册[M].第二版.长沙:湖南科学技术出版社,2015:143-148.
- [10] 高润霖.进一步改善稳定性冠心病的诊治:浅谈“中国稳定性冠心病诊断与治疗指南”亮点[J].中华心血管病杂志,2018,46(11):833-836.
- [11] 胡大一.中国心血管疾病康复/二级预防指南[M],2015版,北京,北京科学技术出版社,2015:84-94.
- [12] VAN DE I E,KOEK H L,DE V R,et al.Efiect of vascular risk factors and diseases on mortality in individuals with dementia:a systematic review and meta-analysis[J].J Am Geriatr Soc,2016,64(1):37-46.
- [13] O’BRIEN J T,THOMAS A.Vascular dementia[J].Lancet,2015,386(4):1698-1706.
- [14] KOVACIC J C,MORENO P,NABEL E G,et al.Cellular senescence,vascular disease,and aging:part 2 of a 2-part review:clinical vascular disease in the elderly[J].Circulation,2011,123(17):1900-1910.
- [15] HOFMAN A,OTT A,BRETELER M M,et al.Atherosclerosis,apolipoprotein E,and prevalence of dementia and Alzheimer's disease in the Rotterdam Study[J].Lancet,1997,349(46):151-154.
- [16] DEDE D S,YAVUZ B,YAVUZ B B,et al.Assessment of endothelial function in Alzheimer's disease:is Alzheimer's disease a vascular disease?[J].J Am Geriatr Soc,2007,55(10):1613-1617.
- [17] STELLOS K,KATSIKL N,TATSIDOU P,et al.Association of platelet activation with vascular cognitive implications indementia development?[J].Curr Vasc Pharmacol,2014,12(1):152-154.
- [18] AKIYAMA H,BARGER S,BAMUM S,et al.Inflammation and Alzheimer's disease[J].Neurobiol Aging,2000,21(3):383-421.
- [19] LATHE R,SAPRONOVA A,KOTELEVTESV Y.Atherosclerosis and Alzheimer diseases with a common cause?Inflammation.oxysterols,vasculature[J].BMC Geriatr,2014,14(3):36-38.
- [20] BRAVERMAN E R,CHEN T J,SCHOOLFIELD J,et al.Delayed P300 latency correlates with abnormal test of variables of attention(TOVA)in adults and predicts early cognitive decline in a clinical setting [J].Adv Ther,2006,23(4):582-600.
- [21] 陈啸,张嘉玮,笪月芳.有氧运动联合认知行为治疗对慢性心力衰竭患者认知功能损伤的改善作用[J].现代医学,2019,47(2):141-145.
- [22] TORJESEN I.Study links drugs for Alzheimer's disease with reduced risk of heart attack and death[J].BMJ,2013,34(6):36-69.